1. Introduction {#sec1}
===============

The great saphenous vein (GSV) is the most commonly used conduit for coronary artery bypass grafting (CABG). The referenced standard method of harvesting the GSV is by way of the open surgical technique. Depending on the required graft length, the average incision will vary between 20 and 40 centimetres. However, in the population of patients undergoing CABG, risk factors for impaired wound healing are overrepresented. Evaluation of 1577 patients that underwent open GSV harvest for CABG in Maastricht, revealed that in 1.5% of patients donor-site infections were diagnosed before discharge \[[@B1]\]. Remarkably this figure increases to 4.6% at 30 days followup and 7.3% at 90 days followup. Therefore 80% of the donor-site infections are diagnosed after discharge, for instance by the patients general physician or cardiologist. Furthermore wound complications are often found to be responsible for additional surgery, prolonged hospital stay, increased hospital costs, and in some cases permanent disability \[[@B1], [@B2]\].

The introduction of endoscopic vein harvesting (EVH) in 1996 seemed a welcome contribution to achieve goals set in modern cardiac surgery, namely, making cardiac surgery less invasive and promote earlier recovery after surgery. Now approximately 15 years after its introduction EVH has conquered an important place in standard clinical care (80% of the CABG procedures conducted in the USA use EVH) \[[@B3]\]. Nevertheless, recent publications have raised doubts whether the quality and durability of an endoscopically harvested vein is comparable with a vein harvested in the traditional open fashion \[[@B29], [@B34]\]. Is EVH indeed a blessing in the attempts to make cardiac surgery less invasive or do the recent publications reveal hidden dangers? This nonsystematic review article aims to give an overview of 15 years of clinical experience with EVH, with appropriate attention for graft quality. Based on a Pubmed search all original papers, review articles, systematic reviews, and meta-analysis were collected. For the search several combinations of the terms endoscopic, minimal invasive, vessel, vein, conduit, harvest, and harvesting were used. Reports investigating radial artery harvest, noncardiac use of vein conduits, the bridging technique, or other nonendoscopic techniques were excluded.

2. Procedure, Learning Curve, and Safety {#sec2}
========================================

2.1. The Procedure {#sec2.1}
------------------

During EVH disposable or reusable systems are used to harvest approximately 35 cm of the upper leg GSV through a 3 cm incision on the medial side of the knee ([Figure 1](#fig1){ref-type="fig"}). By repeating the same procedure in the other direction, the entire GSV (70 cm) can be harvested through a single incision. Several systems are available, most frequently used are the disposable systems, namely, Vasoview by Maquet, VirtuoSaph by Terumo, and Clearglide by Sorin.

2.2. Learning Curve {#sec2.2}
-------------------

Even though EVH systems have become more user-friendly over the years, a significant personal as well as institutional learning curve persists. Analysis of 1348 patients undergoing EVH revealed that the average procedural time of the first 50 cases was 68 minutes, while the procedural time dropped significantly to 23 minutes in the last 200 cases \[[@B4]\]. In general one can expect a personal learning curve of 20--100 procedures, depending on surgical experience.

2.3. Safety {#sec2.3}
-----------

Based on the review of available literature, EVH can be considered a save operative procedure. The few case reports describing EVH specific complications relate to the use of CO~2~ insufflation, namely, severe hypercapnia, subclinical CO~2~ embolization (10.4%), and massive CO~2~ embolization (0.22%) \[[@B4], [@B5]\]. An important preventive measure is reduction of the CO~2~ insufflation pressure, most importantly not allowing the CO~2~ pressure to surpass the central venous pressure.

3. Wound Healing Disturbances {#sec3}
=============================

3.1. Noninfectious Healing Disturbances {#sec3.1}
---------------------------------------

The most complete overview article investigating noninfectious wound healing disturbances is by Athanasiou et al. \[[@B6]\]. This meta-analysis included 27 studies republished between 1995 and 2002, within total 4953 patients. Analysis of 12 randomised controlled trials showed a significant reduction of noninfectious wound healing disturbances (wound drainage, haematoma, oedema, dehiscence, necrosis, need for surgical debridement, and seroma formation) from 13% in open vein harvest to 4% after EVH. The number needed to treat in order to prevent one complication was only 2 for oedema and 13 for the other complications.

Diabetes, hyperlipidemia, obesity, female gender, advanced age, and peripheral vascular disease are known risk factors for wound healing disturbances after open GSV harvest \[[@B2], [@B7]\]. Research has however shown that particularly these high-risk patients benefit most from minimally invasive harvest techniques. For example, in patients with diabetes and obesity no additional risk of wound healing disturbances can be found anymore if EVH is used \[[@B7], [@B8]\].

3.2. Wound Infections {#sec3.2}
---------------------

It is assumed that EVH reduces the number of donor-site infections because it causes less trauma to the surrounding tissue, preserves tissue perfusion, and is less likely to create vital tissue flaps \[[@B9]\]. A meta-analysis from 2003 included all available randomised controlled trials that investigated the incidence of donor-site infections (drainage of pus from the wound, positive wound cultures, and requirement for additional treatment surgical or antibiotic treatment) \[[@B9]\]. Eleven randomised controlled trials, with in total 1156 patients had used endoscopic techniques. All individual studies found reduced or at least equal infection rates after EVH. This meta-analysis revealed that the overall wound infection rate dropped from 13% in the open harvest group to 3% in the EVH group.

4. Postoperative Pain and Mobility {#sec4}
==================================

Postoperative pain quantified using the visual analogue scale, is significantly reduced after EVH compared to the traditional open harvest method \[[@B10]--[@B13]\]. Coppoolse et al. demonstrated that patients undergoing EVH rate their experience of pain 2 points lower (on a 0--10 scale) throughout the whole postoperative period and label themselves pain-free days earlier than their counterparts that underwent open harvest \[[@B13]\]. It is therefore not surprising that a number of studies show that patients undergoing EVH are able to mobilize earlier and are also more mobile at hospital discharge and 6 weeks after surgery \[[@B10], [@B12], [@B14]\].

5. Hospital Length of Stay and Costs {#sec5}
====================================

5.1. Hospital Length of Stay (LOS) {#sec5.1}
----------------------------------

With the reduction of wound complications and earlier mobilisation of patients, it is likely that recovery time and therefore LOS is reduced. Two independent studies have indeed showed reduction in LOS in patients undergoing EVH, respectively, 31 and 34% reduction compared to traditional conduit harvest \[[@B14], [@B15]\]. Another study found a nonsignificant increase of LOS in the EVH group \[[@B16]\]. The remaining 7 available studies investigating this aspect of EVH, found trends towards reduced LOS, without significant differences \[[@B10], [@B11], [@B17]--[@B21]\]. A meta-analysis from 2004 with in total 1757 patients confirmed a reduction of LOS if EVH is used \[[@B6]\].

5.2. Hospital Costs {#sec5.2}
-------------------

In the Netherlands an average disposable-system costs € 400 per procedure. So a legitimate question is whether the additional costs of EVH are justified by the potential benefits. A controlled trial compared the total hospital costs of 100 patients undergoing either EVH or conventional harvest and found no significant differences \[[@B22]\]. The reduction in costs by EVH that the authors had expected, was not found because of the longer use of the operating room on the one hand and failure to reduced LOS on the other. In 2008, a study became available which investigated cost-effectiveness \[[@B23]\]. Because data on health-related quality of life was lacking, postoperative pain and mobilisation was used as a measure of effectiveness. Procedural costs were calculated based on previous publications on LOS, operation-time, and prices of the most expensive EVH system. So it is important to note that costs of readmissions, outpatient visits related to wound problems and costs of wound treatments were not included in his model. Nevertheless, EVH was found to be the most cost-effective method of vein harvest.

6. Cosmetic Result and Quality of Life {#sec6}
======================================

Since the scare after EVH is considerably smaller, it is not surprising that patients are significantly more satisfied with the cosmetic result after EVH then after the traditional harvest \[[@B10], [@B16]\]. However this difference in appreciation, measured using a visual analog scale from 0--10, is mostly notable during the first postoperative period. Six weeks after surgery the cosmetic outcome is equally appreciated \[[@B10]\]. Whatever the case may be, no improvement in quality of life, measured using a Short Form 36 questionnaire, has been demonstrated at 2 and 4 weeks after surgery \[[@B22]\].

7. Graft Quality and Durability {#sec7}
===============================

Suture repairs because of holes or torn side branches of the endoscopically harvested vein are 3--5 times more often necessary then after open vein harvest \[[@B25], [@B24]\]. The presence of these macroscopic lesions make one presume that the endoscopic technique inflicts more trauma to the vessel then the conventional open harvest technique. Furthermore, concerns exist with regards to thermal spread due to diathermic coagulation of side branches, detrimental effects of CO~2~ insufflation, and formation of microscopic clots in the collapsed GSV due to the pressurized working tunnel. It has been suggested that this last concern can be dealt with by early systemic heparinization \[[@B26]\].

7.1. Histological Evaluation {#sec7.1}
----------------------------

Initial studies addressing graft histology did not find differences in injury to the vascular wall and found comparable endothelial integrity after EVH compared to open harvest \[[@B10], [@B12], [@B20], [@B27]\]. One study even found superior endothelial integrity after EVH \[[@B28]\]. However, in 2009 Boston researchers showed evidence of injury to the saphenous vein endothelium during endoscopic harvest \[[@B29]\]. Using three independent techniques (immunohistochemistry, western blot, and multiphoton microscopy), they demonstrated reduced calcium mobilization, nitric oxide production, and esterase activity and reduced levels of von Willebrand factor, all signs of impaired structural and functional viability of saphenous vein endothelium. The authors state that the found detrimental effects on saphenous vein endothelium may lead to decreased graft patency and worse patient outcome.

7.2. Graft Patency {#sec7.2}
------------------

Only a limited number of studies are available that give insights into angiographic implication of possible histological vein injury. Two randomised controlled trials were not able to show significant differences in patency rate between patient undergoing EVH or OVH \[[@B30], [@B25]\]. In both studies followup was however short, namely, 3 and 6 months. Davis et al. on the other hand, compared patients who had undergone EVH 3.7 years prior, to patients that had undergone open harvest 0.7 years earlier \[[@B31]\]. Contrast-enhanced CT showed good patency rate after EVH, which did not differ from the control group with the shorter followup.

7.3. Clinical Outcome {#sec7.3}
---------------------

Studies that investigate clinical outcome after EVH (e.g., recurrent angina, number of reinterventions, recurrent acute myocardial infarction, and survival) are scarcely available. One retrospective study compared patients undergoing EVH with a historical control group \[[@B32]\]. No significant differences in clinically apparent graft failure could be noted. Allen et al. conducted an RCT with a fairly small number of patients (112 isolated CABG patients) and found comparable 5 years event-free survival between the EVH and open harvest group \[[@B33]\]. If a proper power analysis was conducted remains unclear, since no description is provided.

Several months after the Boston group published about inferior histological properties of endoscopically harvested vein an important clinical paper was published in the New England Journal of Medicine. Lopes et al. conducted a secondary analysis on 3000 patients that had been included in the PREVENT IV trial \[[@B34]\]. This phase 3 trial had investigated the effect of ex vivo treatment of saphenous vein conduits with Edifoligide and had not found any beneficial effect on graft patency. In 1753, study subjects the vein graft had been harvested endoscopically and in the remaining 1247 through open surgery. Comparing the two groups revealed that patients who underwent EVH had higher rates of vein graft failure at 12 to 18 months. At 3 years, EVH was associated with higher death (7.4% versus 5.8%), myocardial infarction, or repeat revascularization. It is important to note that the harvest method was not randomly assigned and that details on harvest technique (e.g., used system, experience of the endoscopist, upper or lower leg harvest, and heparin administration) were missing.

A recent observational study compared 5825 patients of whom 34% had undergone EVH \[[@B3]\]. At a followup of 2.6 years no correlation between harvest method and recurrent angina, number of reinterventions, acute coronary syndrome, heart failure or survival could be found. EVH was even associated with a reduced number of readmissions for unstable angina. The most recent publication on clinical outcome is a retrospective case control study \[[@B35]\]. This study was also not able to find differences in the rates of freedom from angina, readmission, need for further antianginals or overall survival. For an overview of the available clinical studies see [Table 1](#tab1){ref-type="table"}.

8. Conclusions {#sec8}
==============

The aim of minimally invasive conduit harvest techniques is to reduce the morbidity and recovery time associated with the procedure, whilst preserving the quality of the conduit \[[@B36]\]. A series of benefits are well founded adequately: EVH results in less wound healing disturbances, less donor-site infections, less postoperative pain, earlier postoperative mobilisation, reduced length of hospital stay, and is likely to be cost-effective. However, recent publications question whether the condition of preserved conduit quality is met. All currently available publication addressing graft quality have important shortcomings, including nonrandomised designs, nonstandardized harvest methods, small sample sizes, retrospective nature, or having only short-term followup. Since EVH has reached an advanced stage of implementation, and has become accepted and by patients highly appreciated by part of standard care, thorough randomised evaluation has become more difficult. Nevertheless a moral obligation exists to ensure without any doubt safety and durability of the endoscopically harvested conduit, since conduit quality is likely to influence clinical outcome of CABG, the golden standard for a considerable portion of patients with multivessel coronary artery disease. Therefore randomised controlled trials are necessary to settle this issue indefinitely. Aim of such a trial should be to show *non*inferiority of EVH versus open harvest. Since we now have reason to suspect clinical implications of possible inferior graft quality based on the findings of Lopes et al., the only relevant endpoint is MACE (Major Adverse Cardiac Events). The comparison with PCI versus CABG debate is in some part valid. The high number of covariates influencing in the primary endpoint will demand hundreds of study subjects in each study arm. The study of Lopes et al. also learned us that followup should be at least one year and that the most interesting secondary endpoint would be graft patency at one year. Obviously such a study would be costly, while in this field profit margins are considerably smaller then in the PCI industry. Willingness of companies to invest large amount of money in such studies will probably be less. Nevertheless a randomised controlled trial was initiated by a manufacturer of EVH systems, namely, the OPTION study. This study, that is, a single centre, 100 patient trial, investigating graft patency among other endpoint, one year after CABG surgery. Results of this and future initiatives will be eagerly awaited, since they will determine the future of endoscopic vein harvesting.
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![Endoscopic vein harvesting. (a) The first step is the identification of the great saphenous vein (GSV) through a 3-cm incision near the knee. (b) The next step is the dissection of the vein from the surrounding subcutaneous tissue. (c) After creating a tunnel by means of CO~2~ insufflation, all side branches of the GSV are identified, coagulated using diathermy and transected. (d) The final result is demonstrated, 35 cm of vein harvested through a 3 cm incision near the knee and a 3-mm counterincision in the groin (arrow).](CRP2011-813512.001){#fig1}
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Graft quality in terms of graft patency and clinical outcome.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, yr                         Method                            *N*        Followup      Patency rate   Clinical outcome (EVH versus open harvest)   
  ---------------------------------- -------------------------------- ----------- ------------- --------------- -------------------------------------------- -------------------------------------------------------------------------------------------------
  Felisky et al., 2002 \[[@B32]\]    retrospective                    380 EVH\    In-hospital   ---\            ---                                          no significant differences in rate of clinically apparent early graft failure
                                                                      340 OVH                   ---                                                          

  Allen et al., 2003 \[[@B33]\]      RCT                              54 EVH\     5 yr          ---\            ---                                          equal 5 yr event-free survival (events: death, AMI, recurrent AP)
                                                                      58 OVH                    ---                                                          

  Perrault et al., 2004 \[[@B30]\]   RCT, CAG                         40 EVH\     3 m           85%\            .991                                         ---
                                                                      40 OVH                    84%                                                          

  Davis et al., 2004 \[[@B31]\]      retrospective, CE-CT             51 EVH\     3.7 yr\       95%\            n.s.                                         ---
                                                                      50 OVH      0.7 yr        95%                                                          

  Yun et al., 2005 \[[@B25]\]        RCT, CAG                         100 EVH\    6 m           68%\            .584                                         ---
                                                                      100 OVH                   70%                                                          

  Lopes et al., 2009 \[[@B34]\]      prospective nonrandomized, CAG   1753 EVH\   3 yr          73%\            \<.001                                       associated with higher rates of death, myocardial infraction, or repeat revascularization
                                                                      1247 OVH                  77%                                                          

  Ouzounian et al., 2010 \[[@B3]\]   prospective observational        2004 EVH\   2.6 yr        ---\            ---                                          not an independent predictor of in-hospital or midterm adverse outcome
                                                                      3821 OVH                  ---                                                          

  Kirmani et al., 2010 \[[@B35]\]    case-control                     89 EVH\     17 m\         ---\            ---                                          no difference in the rates of freedom from angina, readmission or need for further antianginals
                                                                      182 OVH     38 m          ---                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ns: not significant; EVH: endoscopic vein harvesting, OVH: open vein harvesting, CAG: coronary angiogram, RCT: randomized controlled trial; AMI: acute myocardial infarction; AP: angina pectoris; CE-CT: contrast-enhanced CT.
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